Acute Effects of Aerosolized Iloprost in COPD Related Pulmonary Hypertension - A Randomized Controlled Crossover Trial

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Boeck, Lucas ^a   Tamm, Michael ^a   Grendelmeier, Peter ^a   Stolz, Daiana ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON DIOXIDE; ILOPROST; PLACEBO;

AEROSOL; AGED; ARTERIAL CARBON DIOXIDE TENSION; ARTICLE; BLOOD GAS ANALYSIS; CARBON DIOXIDE MEASUREMENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; EXERCISE TOLERANCE; FEMALE; HUMAN; LOW DRUG DOSE; MALE; OXYGEN CONSUMPTION; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT FAILURE; WALKING SPEED;

ADMINISTRATION, INHALATION; ADULT; AEROSOLS; AGED; CROSS-OVER STUDIES; FEMALE; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; MALE; OXYGEN; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY GAS EXCHANGE;

EID: 84871665217     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052248     Document Type: Article

References (35)

1. Mannino DM, (2002) COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 121: 121S-126S.
2. Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E, (1999) Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 159: 158-164.
3. Oswald-Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A, et al. (1995) Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 107: 1193-1198.
4. Sims MW, Margolis DJ, Localio AR, Panettieri RA, Kawut SM, et al. (2009) Impact of pulmonary artery pressure on exercise function in severe COPD. Chest 136: 412-419.
5. Bogaard HJ, Dekker BM, Arntzen BW, Woltjer HH, van Keimpema AR, et al. (1998) The haemodynamic response to exercise in chronic obstructive pulmonary disease: assessment by impedance cardiography. Eur Respir J 12: 374-379.
6. Sabit R, Bolton CE, Fraser AG, Edwards JM, Edwards PH, et al. (2010) Sub-clinical left and right ventricular dysfunction in patients with COPD. Respiratory medicine 104: 1171-1178.
7. Barr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright PL, et al. (2010) Percent emphysema, airflow obstruction, and impaired left ventricular filling. The New England journal of medicine 362: 217-227.
8. Melot C, Hallemans R, Naeije R, Mols P, Lejeune P, (1984) Deleterious effect of nifedipine on pulmonary gas exchange in chronic obstructive pulmonary disease. Am Rev Respir Dis 130: 612-616.
9. Agusti AG, Barbera JA, Roca J, Wagner PD, Guitart R, et al. (1990) Hypoxic pulmonary vasoconstriction and gas exchange during exercise in chronic obstructive pulmonary disease. Chest 97: 268-275.
10. Stolz D, Rasch H, Linka A, Di Valentino M, Meyer A, et al. (2008) A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 32: 619-628.
11. Rietema H, Holverda S, Bogaard HJ, Marcus JT, Smit HJ, et al. (2008) Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J 31: 759-764.
12. Walmrath D, Schneider T, Schermuly R, Olschewski H, Grimminger F, et al. (1996) Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. American journal of respiratory and critical care medicine 153: 991-996.
13. Zwissler B, Kemming G, Habler O, Kleen M, Merkel M, et al. (1996) Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. American journal of respiratory and critical care medicine 154: 1671-1677.
14. Vonbank K, Ziesche R, Higenbottam TW, Stiebellehner L, Petkov V, et al. (2003) Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD. Thorax 58: 289-293.
15. Adnot S, Kouyoumdjian C, Defouilloy C, Andrivet P, Sediame S, et al. (1993) Hemodynamic and gas exchange responses to infusion of acetylcholine and inhalation of nitric oxide in patients with chronic obstructive lung disease and pulmonary hypertension. The American review of respiratory disease 148: 310-316.
16. Roger N, Barbera JA, Roca J, Rovira I, Gomez FP, et al. (1997) Nitric oxide inhalation during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 156: 800-806.
17. Lee JD, Taraseviciene-Stewart L, Keith R, Geraci MW, Voelkel NF, (2005) The expression of prostacyclin synthase is decreased in the small pulmonary arteries from patients with emphysema. Chest 128: 575S.
18. Nana-Sinkam SP, Lee JD, Stearman R, Sakao S, Sotto-Santiago S, et al. (2006) Prostacyclin synthase in smoking-related lung disease. Proceedings of the American Thoracic Society 3: 517.
19. Olschewski H, Ghofrani HA, Walmrath D, Schermuly R, Temmesfeld-Wollbruck B, et al. (1999) Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. American journal of respiratory and critical care medicine 160: 600-607.
20. Dernaika TA, Beavin M, Kinasewitz GT, (2010) Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Respiration; international review of thoracic diseases 79: 377-382.
21. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, et al. (2007) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. American journal of respiratory and critical care medicine 176: 532-555.
22. Gessler T, Schmehl T, Hoeper MM, Rose F, Ghofrani HA, et al. (2001) Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. Eur Respir J 17: 14-19.
23. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, et al. (1993) Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. The European respiratory journal Supplement 16: 5-40.
24. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, et al. (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology 34: 1219-1263.
25. Attinger A, Tuller C, Souren T, Tamm M, Schindler C, et al. (2006) Feasibility of mobile cardiopulmonary exercise testing. Swiss Med Wkly 136: 13-18.
26. Tueller C, Kern L, Azzola A, Baty F, Condrau S, et al. (2010) Six-minute walk test enhanced by mobile telemetric cardiopulmonary monitoring. Respiration; international review of thoracic diseases 80: 410-418.
27. ATS statement: guidelines for the six-minute walk test. American journal of respiratory and critical care medicine 166: 111-117.
28. Aliverti A, Macklem PT, (2008) Last Word on Point:Counterpoint: The major limitation to exercise performance in COPD is 1) inadequate energy supply to the respiratory and locomotor muscles, 2) lower limb muscle dysfunction, 3) dynamic hyperinflation. Journal of applied physiology 105: 763.
29. Simonneau G, Escourrou P, Duroux P, Lockhart A, (1981) Inhibition of hypoxic pulmonary vasoconstriction by nifedipine. The New England journal of medicine 304: 1582-1585.
30. Kalra L, Bone MF, (1993) Effect of nifedipine on physiologic shunting and oxygenation in chronic obstructive pulmonary disease. The American journal of medicine 94: 419-423.
31. Blanco I, Gimeno E, Munoz PA, Pizarro S, Gistau C, et al. (2010) Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. American journal of respiratory and critical care medicine 181: 270-278.
32. Alp S, Skrygan M, Schmidt WE, Bastian A, (2006) Sildenafil improves hemodynamic parameters in COPD-an investigation of six patients. Pulm Pharmacol Ther 19: 386-390.
33. Rosengarten B, Schermuly RT, Voswinckel R, Kohstall MG, Olschewski H, et al. (2006) Sildenafil improves dynamic vascular function in the brain: studies in patients with pulmonary hypertension. Cerebrovascular diseases 21: 194-200.
34. Boerrigter BG, Bogaard HJ, Trip P, Groepenhoff H, Rietema H, et al. (2012) Ventilatory and cardiocirculatory exercise profiles in COPD: the role of pulmonary hypertension. Chest.
35. Halpern SD, Taichman DB, (2009) Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest 136: 37-43.